Compare RNTX & ZDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RNTX | ZDAI |
|---|---|---|
| Founded | 2001 | 2022 |
| Country | United States | Hong Kong |
| Employees | 11 | 33 |
| Industry | Biotechnology: Pharmaceutical Preparations | General Bldg Contractors - Nonresidential Bldgs |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.0M | 35.4M |
| IPO Year | N/A | N/A |
| Metric | RNTX | ZDAI |
|---|---|---|
| Price | $1.26 | $3.66 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 96.1K | 3.5K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.02 | $0.20 |
| 52 Week High | $2.22 | $6.56 |
| Indicator | RNTX | ZDAI |
|---|---|---|
| Relative Strength Index (RSI) | 51.38 | 52.88 |
| Support Level | $1.07 | $3.64 |
| Resistance Level | $1.30 | $4.71 |
| Average True Range (ATR) | 0.12 | 0.27 |
| MACD | -0.00 | -0.20 |
| Stochastic Oscillator | 42.86 | 27.93 |
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.